1Epstein J, Yang X. Prostate Biopsy Interpretation. Philadelphia: Lippincott Williams & Wilkins, 2002.
2Young R, Sringley J, Amin M. Tumors of the prostate glands, seminal vesicles, male urethra, and penis. Washington, D.C.: Armed Forces Institute of Pathology, 2000.
3Wang MC, Valenzuela LA, Murphy GP, et al. A simplified purification procedure for human prostate antigen. Oncology, 1982, 39:1-5.
4Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol,1999,162:293-306.
5Beckett ML, Lipford GB, Haley CL, et al. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res, 1991, 51:1326-1333.
6Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412:822-826.
7Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol, 1984, 114:309-321.
8Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol, 2000, 157:1769-1775.
9Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol, 1995,19:251-260.
10Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res, 2000, 60:1677-1682.
10Bastwick DG.Predictive factors in prostate cancer current concepts from the 1999 college of American Pathologists Conference on solid tumor prognostic factors and the 1999 World Health Organization second international consultation on prostate cancer[J].Semin Urol Oncol, 1999, 17(4) :222.
